AGP Executive Report
Last update: 10 hours agoDrug-Price Politics: A fresh German push to cap medicine spending is framed as cost-cutting, but the argument is that it simply shifts the bill to the US—where patients bankroll much of global pharma R&D—raising new pressure for reciprocity. China Business Mood: EU firms in China report tentative improvement in profitability and growth outlook, yet confidence stays fragile amid tougher competition, regulatory uncertainty, and market access barriers (with autos still hit by price wars). Auto Industry Shift: Europe’s April car market kept growing on electrified demand, while Chinese brands gained share—export momentum rose again in April, despite tariffs. Industrial Energy & Resilience: Solid-oxide electrolysis moves toward real deployment, while Tallinn backs energy-independent smart bus stops and UK businesses are urged to plan for heat disruptions. Biotech & Manufacturing: Precision BioSciences presented ELIMINATE-B clinical data on cccDNA elimination/inactivation; Pacifico Biolabs raised €7m to scale alternative-protein production in Germany. Defense Demand: Elbit secured a ~$1.4b European modernization contract and pushed backlog past €30b.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
